Sponsor

Janssen-Cilag International NV

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Janssen-Cilag International NV appears in 23 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials23
Recruiting shown0
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

23 shown
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare SettingsNCT04940039 · lead sponsor · 2021-07-22
COMPLETED
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderNCT04338321 · lead sponsor · 2020-08-21
COMPLETED
A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy AdultsNCT03768609 · lead sponsor · 2018-12-06
COMPLETED
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthlyNCT03809325 · lead sponsor · 2018-11-21
COMPLETED
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During RamadanNCT02737657 · lead sponsor · 2016-04-01
COMPLETED
A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive DisorderNCT02476058 · lead sponsor · 2015-06-11
COMPLETED
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentNCT01709084 · lead sponsor · 2013-10-02
COMPLETED
A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital SettingNCT01926912 · lead sponsor · 2013-05-01
COMPLETED
Telaprevir Open-Label Study in Co-Infected PatientsNCT01500616 · lead sponsor · 2012-06-01
COMPLETED
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)NCT01513941 · lead sponsor · 2012-04-01
COMPLETED
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentNCT01448707 · lead sponsor · 2012-03-15
COMPLETED
Paliperidone Palmitate Flexible Dosing in SchizophreniaNCT01281527 · lead sponsor · 2010-11-01
COMPLETED
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral AntipsychoticsNCT01081769 · lead sponsor · 2010-02-01
COMPLETED
InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral AntipsychoticsNCT01026285 · lead sponsor · 2009-06-01
COMPLETED
A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected PatientsNCT00903682 · lead sponsor · 2009-06-01
COMPLETED
Observational Study to Assess Outcomes During Antipsychotic Treatment With Paliperidone ER or Other Oral AntipsychoticsNCT00696813 · lead sponsor · 2008-06-01
COMPLETED
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With SchizophreniaNCT00645099 · lead sponsor · 2007-10-01
COMPLETED
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With SchizophreniaNCT00566631 · lead sponsor · 2007-07-01
COMPLETED
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/RitonavirNCT00458302 · lead sponsor · 2007-06-01
COMPLETED
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With SchizophreniaNCT00460512 · lead sponsor · 2007-04-25
COMPLETED
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderNCT00216476 · lead sponsor · 2004-10-01
COMPLETED
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCERNCT03712956 · collaborator · 2016-03-25
UNKNOWN
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.NCT00111189 · collaborator · 2005-02-01
COMPLETED

Drugs studied in this sponsor's trials

18 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Janssen-Cilag International NV as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
paliperidone palmitate2
placebo2
telaprevir2
aripiprazole1
cyclosporine1
darunavir1
diphenhydramine1
efavirenz1
paliperidone palmitate RxCUI 858045 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials telaprevir RxCUI 1102261 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials aripiprazole RxCUI 89013 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cyclosporine RxCUI 3008 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial darunavir RxCUI 460132 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial diphenhydramine RxCUI 3498 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial efavirenz RxCUI 195085 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial emtricitabine RxCUI 276237 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial olanzapine RxCUI 61381 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paliperidone RxCUI 679314 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial peginterferon alfa-2a RxCUI 120608 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial quetiapine RxCUI 51272 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ribavirin RxCUI 9344 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial rilpivirine RxCUI 1102270 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial risperidone 3 MG RxCUI 316646 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ritonavir RxCUI 85762 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial tenofovir disoproxil fumarate RxCUI 322248 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor21
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.